AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2877953 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg per day dihydroergotamine
Number of subjects: 0
Study 2877953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3142203 — intervention group
Group type: EXPERIMENTAL
Intervention: Strapping with an inelastic tape
Number of subjects: 200
Study 3142203 — intervention group
Group type: COMPARATOR
Intervention: Operation and a walking cast
Number of subjects: 200
Study 3142203 — intervention group
Group type: COMPARATOR
Intervention: Walking cast alone
Number of subjects: 200
Study 31410765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenges containing Lactobacillus reuteri taken twice daily for 90 days
Number of subjects: 20
Study 31410765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 31005243 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 399
Study 31005243 — intervention group
Group type: COMPARATOR
Intervention: PORT
Number of subjects: 399
Study 28177568 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to parents' recorded voice during sedation
Number of subjects: 50
Study 28177568 — intervention group
Group type: COMPARATOR
Intervention: Not listening to parents' recorded voice during sedation
Number of subjects: 50
Study 26048186 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 15
Study 26048186 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 15
Study 26048186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23481576 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy only
Number of subjects: 751
Study 23481576 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy with biopsy
Number of subjects: 751
Study 23481576 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy with LLETZ
Number of subjects: 751
Study 21451152 — intervention group
Group type: EXPERIMENTAL
Intervention: EZG(RTG) 1,200 mg/day
Number of subjects: 306
Study 21451152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 18713759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078
Study 18713759 — intervention group
Group type: COMPARATOR
Intervention: Major bleeding
Number of subjects: 20078
Study 16708359 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 57
Study 16708359 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 57
Study 16708359 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 57
Study 16708359 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 57
Study 15301297 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE levels in serum
Number of subjects: 74
Study 15301297 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral food challenges (cow milk, hen egg, wheat)
Number of subjects: 74
Study 15301297 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet
Number of subjects: 74
Study 11810123 — intervention group
Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP) at 0 cmH2O
Number of subjects: 10
Study 11810123 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP) at 8 cmH2O
Number of subjects: 10
Study 8996417 — intervention group
Group type: EXPERIMENTAL
Intervention: USA treatment
Number of subjects: 2972
Study 8996417 — intervention group
Group type: COMPARATOR
Intervention: Other countries treatment
Number of subjects: 2972
Study 8491245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (Group 1, n = 6)
Number of subjects: 12
Study 8491245 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg (Group 2, n = 6)
Number of subjects: 12
Study 8491245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and doxazosin
Number of subjects: 12
Study 8491245 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg (Group 2) with addition of Nifedipine
Number of subjects: 12
Study 8491245 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin 2 mg (Group 2)
Number of subjects: 12
Study 3695671 — intervention group
Group type: EXPERIMENTAL
Intervention: Group practice model
Number of subjects: 50
Study 3695671 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical clinic
Number of subjects: 50
Study 30166303 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 110
Study 30166303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 110
Study 30166303 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 110
Study 30166303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 26755229 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid preload with 0.5 L of 6% w/v hydroxyethyl starch solution
Number of subjects: 60
Study 26755229 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic IV infusion of 15 mg ephedrine
Number of subjects: 60
Study 25401512 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL-shell technique (Group II)
Number of subjects: 80
Study 25401512 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification (Group I)
Number of subjects: 80
Study 23347711 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and counseling provision using the 'patient journey' model
Number of subjects: 158
Study 23347711 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 158
Study 20880872 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-CPAP (n=124)
Number of subjects: 250
Study 20880872 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control (n=126)
Number of subjects: 250
Study 18358724 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality‐based treadmill training
Number of subjects: 20
Study 18358724 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training (control)
Number of subjects: 20
Study 16641468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (Boost Plus)
Number of subjects: 0
Study 14716631 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized optimum adaptation pattern derived for each patient
Number of subjects: 0
Study 10026369 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 6-ppm dose of inhaled nitric oxide (iNO)
Number of subjects: 29
Study 10026369 — intervention group
Group type: COMPARATOR
Intervention: 20 ppm iNO for 4 h followed by 6 ppm
Number of subjects: 29
Study 10026369 — intervention group
Group type: EXPERIMENTAL
Intervention: Either treatment
Number of subjects: 29
Study 8677926 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for functional dyspepsia
Number of subjects: 52
Study 8677926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1912715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of senna pods and Goleytely solution
Number of subjects: 80
Study 1912715 — intervention group
Group type: COMPARATOR
Intervention: Goleytely solution (7 litres)
Number of subjects: 80
Study 1912715 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone (additional administration)
Number of subjects: 80
Study 6761136 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg
Number of subjects: 60
Study 6761136 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg
Number of subjects: 60
Study 6761136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30300800 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone treatment for 12 weeks
Number of subjects: 120
Study 30300800 — intervention group
Group type: COMPARATOR
Intervention: Dropped out of naltrexone treatment
Number of subjects: 120
Study 27150606 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual clinical practice augmented by decision aid websites
Number of subjects: 48
Study 27150606 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice alone
Number of subjects: 48
Study 24801451 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-point scale
Number of subjects: 82
Study 24801451 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-point scale
Number of subjects: 82
Study 24801451 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-point scale
Number of subjects: 82
Study 21810843 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 2270
Study 21810843 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotics
Number of subjects: 2270
Study 21810843 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2270
Study 21810843 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB
Number of subjects: 2270
Study 21810843 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (statins, antithrombotics, ACEI/ARB)
Number of subjects: 2270
Study 20623976 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral probe feeding (EEPF) conduction
Number of subjects: 32
Study 18813830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel (Arm A): Cisplatin 80 mg/m² and paclitaxel 175 mg/m² on day 1, repeated every 3 weeks.
Number of subjects: 108
Study 18813830 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-etoposide (Arm B): Cisplatin 80 mg/m² on day 1 and etoposide 120 mg/m² per day on days 1-3, repeated every 3 weeks.
Number of subjects: 108
Study 15741845 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation training (EMS) - 30 contractions (4‐s duration, 85 Hz), 3 times a week for 3 weeks
Number of subjects: 17
Study 15741845 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation training (EMS)
Number of subjects: 17
Study 15493240 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic Organizers (GOs)
Number of subjects: 0
Study 15493240 — intervention group
Group type: COMPARATOR
Intervention: No Graphic Organizers (No GO)
Number of subjects: 0
Study 10460524 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol, sufentanil and atracurium
Number of subjects: 40
Study 10460524 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (group 2)
Number of subjects: 40
Study 10460524 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (group 1)
Number of subjects: 40
Study 7876922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lauric acid diet (4% of energy from lauric acid)
Number of subjects: 15
Study 7876922 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid diet (4% of energy from palmitic acid)
Number of subjects: 15
Study 7876922 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet (4% of energy from monoenes)
Number of subjects: 15
Study 2797847 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 18
Study 2797847 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg B.I.D
Number of subjects: 18
Study 2797847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 18
Study 788890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oral cyclophosphamide
Number of subjects: 113
Study 788890 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed staging system
Number of subjects: 113
Study 788890 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral lymphocyte count
Number of subjects: 113
Study 788890 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor site
Number of subjects: 113
Study 788890 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional node involvement
Number of subjects: 113
Study 30923036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab/ipilimumab combination therapy
Number of subjects: 0
Study 30923036 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4 (ipilimumab)
Number of subjects: 0
Study 30923036 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapies (nivolumab, pembrolizumab)
Number of subjects: 0
Study 30923036 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 27832248 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular game treatment
Number of subjects: 28
Study 27832248 — intervention group
Group type: COMPARATOR
Intervention: Patching treatment
Number of subjects: 28
Study 27832248 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular game treatment (after crossover)
Number of subjects: 28
Study 27832248 — intervention group
Group type: COMPARATOR
Intervention: Patching treatment (after crossover)
Number of subjects: 28
Study 24077833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES 130 kDa/0.4)
Number of subjects: 30
Study 24077833 — intervention group
Group type: COMPARATOR
Intervention: Ringer’s acetate (RAC)
Number of subjects: 30
Study 22448010 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 1291
Study 22448010 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected individuals
Number of subjects: 1291
Study 22448010 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1291
Study 22448010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CD4 count
Number of subjects: 1291
Study 22448010 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age and HCV infection
Number of subjects: 1291
Study 19915859 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise (HIIE) mode A
Number of subjects: 19
Study 19915859 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise (HIIE) mode C
Number of subjects: 19
Study 18042304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (1 mg via nasal spray)
Number of subjects: 47
Study 18042304 — intervention group
Group type: EXPERIMENTAL
Intervention: High tense arousal (exposed to hard anagrams)
Number of subjects: 47
Study 18042304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine and high tense arousal combined
Number of subjects: 47
Study 18042304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched to nicotine)
Number of subjects: 47
Study 16163915 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil
Number of subjects: 30
Study 16163915 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 30
Study 14607201 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 26
Study 14607201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 26
Study 10372240 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/day) for 6 months
Number of subjects: 30
Study 10372240 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (1.25-7.5 mg/day) with diet therapy
Number of subjects: 30
Study 1932613 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (DTZ) alone
Number of subjects: 14
Study 1932613 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (DTZ) in combination with Propranolol (PPL)
Number of subjects: 14
Study 1932613 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (PPL) alone
Number of subjects: 14
Study 1932613 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PPL) in combination with Diltiazem (DTZ)
Number of subjects: 14
Study 6853404 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin administered intravenously
Number of subjects: 16
Study 30539221 — intervention group
Group type: EXPERIMENTAL
Intervention: Freehand patellar resection technique
Number of subjects: 100
Study 30539221 — intervention group
Group type: COMPARATOR
Intervention: Cutting guide patellar resection technique
Number of subjects: 100
Study 30360820 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1660
Study 30360820 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1660
Study 26767506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 53
Study 26767506 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 53
Study 24485497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone 240 min before delay and trace acquisition (slow cort)
Number of subjects: 63
Study 24485497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone 60 min before delay and trace acquisition (rapid cort)
Number of subjects: 63
Study 24485497 — intervention group
Group type: COMPARATOR
Intervention: Placebo at both times
Number of subjects: 63
Study 23012931 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth Subgallate/Borneol (Suile) dressing (BSB group, n = 25)
Number of subjects: 35
Study 23012931 — intervention group
Group type: COMPARATOR
Intervention: Intrasite gel (IG group, n = 10)
Number of subjects: 35
Study 23012931 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth Subgallate/Borneol (Suile) dressing (BSB group)
Number of subjects: 35
Study 23012931 — intervention group
Group type: COMPARATOR
Intervention: Intrasite gel (IG group)
Number of subjects: 35
Study 19879724 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 44
Study 19879724 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 44
Study 17338899 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily budesonide (800 microg)
Number of subjects: 0
Study 17338899 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily budesonide (400 microg)
Number of subjects: 0
Study 16294343 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention (4 sessions attended together or by the man alone)
Number of subjects: 84
Study 12234308 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (2.5 g/m(2) or 5 g/m(2) x 3/day)
Number of subjects: 21
Study 12234308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9820258 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy and soft tissue therapy
Number of subjects: 75
Study 9820258 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment and soft tissue therapy
Number of subjects: 75
Study 8819662 — intervention group
Group type: EXPERIMENTAL
Intervention: Code A (novel time release preparation of ferrous sulphate)
Number of subjects: 60
Study 8819662 — intervention group
Group type: COMPARATOR
Intervention: Code B (sustained release ferrous sulphate preparation)
Number of subjects: 60
Study 8819662 — intervention group
Group type: EXPERIMENTAL
Intervention: Code A
Number of subjects: 60
Study 8819662 — intervention group
Group type: COMPARATOR
Intervention: Code B
Number of subjects: 60
Study 1663261 — intervention group
Group type: EXPERIMENTAL
Intervention: WC3 rotavirus vaccine (two doses at 1-month interval, first dose at 3 months of age)
Number of subjects: 472
Study 1663261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses at 1-month interval, first dose at 3 months of age)
Number of subjects: 472
Study 1663261 — intervention group
Group type: EXPERIMENTAL
Intervention: WC3 rotavirus vaccine
Number of subjects: 472
Study 7291955 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmic acid
Number of subjects: 126
Study 7291955 — intervention group
Group type: COMPARATOR
Intervention: Yttrium-90
Number of subjects: 126
Study 31629718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating (attending to the sensory properties of food)
Number of subjects: 60
Study 30111193 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 51
Study 30111193 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 51
Study 27811319 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC alone
Number of subjects: 406
Study 27811319 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC plus emtricitabine (FTC)
Number of subjects: 406
Study 27811319 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC plus tenofovir disoproxil fumarate (TDF)
Number of subjects: 406
Study 27811319 — intervention group
Group type: COMPARATOR
Intervention: TDF plus FTC
Number of subjects: 406
Study 27657193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejaculation < 3 days before MRI (Group 1)
Number of subjects: 238
Study 27657193 — intervention group
Group type: COMPARATOR
Intervention: Ejaculation ≥ 3 days before MRI (Group 2)
Number of subjects: 238
Study 25424299 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulse ultrasound stimulation (LIPUS) treatment 15 min/day
Number of subjects: 81
Study 25424299 — intervention group
Group type: COMPARATOR
Intervention: Control group (immobilized by plaster support and cast)
Number of subjects: 81
Study 21617191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 74
Study 21617191 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 74
Study 18839137 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular failure (RVF) present in patients with ARDS
Number of subjects: 145
Study 18839137 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RVF (RVF+)
Number of subjects: 145
Study 18839137 — intervention group
Group type: COMPARATOR
Intervention: Patients without RVF (RVF-)
Number of subjects: 145
Study 18839137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume in RVF+ patients
Number of subjects: 145
Study 18839137 — intervention group
Group type: EXPERIMENTAL
Intervention: I/E ratio in RVF+ patients
Number of subjects: 145
Study 18839137 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau pressure in RVF+ patients
Number of subjects: 145
Study 18839137 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis factors associated with day-90 mortality
Number of subjects: 145
Study 18090188 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 124
Study 18090188 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator
Number of subjects: 124
Study 18090188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (partners of patients with antiarrhythmic drugs and implantable cardioverter defibrillator)
Number of subjects: 124
Study 15347634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg orally twice daily for 3 days
Number of subjects: 455